{"id":745750,"date":"2018-03-14T18:30:00","date_gmt":"2018-03-14T18:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/first-line-lung-cancer-data-and-other-new-research-from-mercks-broad-oncology-program-to-be-presented-at-aacr-annual-meeting\/"},"modified":"2025-11-07T01:27:26","modified_gmt":"2025-11-07T06:27:26","slug":"first-line-lung-cancer-data-and-other-new-research-from-mercks-broad-oncology-program-to-be-presented-at-aacr-annual-meeting","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/first-line-lung-cancer-data-and-other-new-research-from-mercks-broad-oncology-program-to-be-presented-at-aacr-annual-meeting\/","title":{"rendered":"First-Line Lung Cancer Data and Other New Research from Merck\u2019s Broad Oncology Program to be Presented at AACR Annual Meeting"},"content":{"rendered":"<p class=\"bwalignc\">       Late-Breaker Presentation of Overall Survival and Progression-Free        Survival Results from Pivotal Phase 3 KEYNOTE-189 Trial with KEYTRUDA <sup> \u00ae <\/sup>         (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy in First-Line        Treatment of Advanced Nonsquamous Non-Small Cell Lung Cancer     <\/p>\n<p class=\"bwalignc\">       First-Time KEYTRUDA Data Including Recurrence-Free Survival from        Phase 3 KEYNOTE-054 Study, in Collaboration with EORTC, in Patients with        Stage III Surgically Resected High-Risk Melanoma     <\/p>\n<p class=\"bwalignc\">       Additional Research with KEYTRUDA, Investigational STING Agonist        (MK-1454) and Merck\u2019s Collaboration with AstraZeneca for LYNPARZA <sup> \u00ae <\/sup>         (olaparib) to be Presented     <\/p>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that new research from Merck\u2019s broad oncology clinical<br \/>\n      program \u2013 across several major tumor types, as monotherapy and in<br \/>\n      combination \u2013 will be presented at the American Association for Cancer<br \/>\n      Research (AACR) Annual Meeting 2018 in Chicago from April 14-18. For the<br \/>\n      first time, data from the pivotal phase 3 KEYNOTE-189 trial with KEYTRUDA<sup>\u00ae<\/sup><br \/>\n      (pembrolizumab), Merck\u2019s anti-PD-1 therapy, in combination with<br \/>\n      pemetrexed (ALIMTA<sup>\u00ae<\/sup>) and cisplatin or carboplatin for the<br \/>\n      first-line treatment of metastatic nonsquamous non-small cell lung<br \/>\n      cancer (NSCLC) will be presented (Abstract #CT075). In January 2018,<br \/>\n      Merck announced the KEYNOTE-189 study met its dual primary endpoints,<br \/>\n      and the KEYTRUDA combination resulted in significantly longer overall<br \/>\n      survival (OS) and progression-free survival (PFS) than pemetrexed plus<br \/>\n      platinum chemotherapy alone. In addition, results from the phase 3<br \/>\n      KEYNOTE-054 trial, in collaboration with the European Organization for<br \/>\n      Research and Treatment of Cancer (EORTC), studying KEYTRUDA in adjuvant<br \/>\n      melanoma will be presented (Abstract #CT001). As previously announced,<br \/>\n      this is the first KEYTRUDA trial to demonstrate a significant<br \/>\n      recurrence-free survival (RFS) benefit in the adjuvant treatment setting<br \/>\n      for stage III melanoma.\n    <\/p>\n<p>\n      \u201cOur global efforts in immuno-oncology research, anchored by KEYTRUDA,<br \/>\n      are fueled by a commitment to improve the lives of patients suffering<br \/>\n      from malignant disease,\u201d said Dr. Roger M. Perlmutter, president, Merck<br \/>\n      Research Laboratories. \u201cNew studies to be presented at AACR, including<br \/>\n      our KEYNOTE-189 and -054 trials in first-line lung cancer and adjuvant<br \/>\n      melanoma, respectively, demonstrate the progress that we and our<br \/>\n      colleagues have made in developing treatment regimens for a broad range<br \/>\n      of cancers.\u201d\n    <\/p>\n<p>\n      \u201cThe science of immunotherapy has advanced significantly in recent<br \/>\n      years, and Merck is forging new ground through its research efforts. At<br \/>\n      the Cancer Research Institute, we support the discovery of new treatment<br \/>\n      options for people with cancer and we are very excited about the new<br \/>\n      research with KEYTRUDA in first-line lung cancer and other cancers to be<br \/>\n      presented at AACR,\u201d said Jill O&#8217;Donnell-Tormey, Ph.D., chief executive<br \/>\n      officer and director of scientific affairs, Cancer Research Institute<br \/>\n      (CRI).\n    <\/p>\n<p>\n      With KEYTRUDA (pembrolizumab) and a growing early pipeline of 20 novel<br \/>\n      mechanisms, Merck has become a leader in immuno-oncology research with<br \/>\n      the largest clinical program in the industry. Data from Merck\u2019s broad<br \/>\n      portfolio including KEYTRUDA, internally-discovered investigational<br \/>\n      STING agonist (MK-1454), and several collaborations including with<br \/>\n      AstraZeneca for the PARP inhibitor LYNPARZA<sup>\u00ae<\/sup> (olaparib), will<br \/>\n      be featured in more than 20 oral plenary and poster presentations.\n    <\/p>\n<p>\n      Select data highlights at AACR include:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        <b>KEYNOTE-189:<\/b> Randomized, double-blind, phase 3 study of<br \/>\n        pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum<br \/>\n        as first-line therapy for metastatic NSCLC. Top-line results showed<br \/>\n        that the KEYTRUDA combination improved OS and PFS in the first-line<br \/>\n        treatment of nonsquamous NSCLC. Abstract #CT075. L Gandhi. Plenary<br \/>\n        Session: Monday, April 16, 10:30 a.m.-12:30 p.m. CDT.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <b>KEYNOTE-054 (EORTC1325):<\/b> Pembrolizumab versus placebo after<br \/>\n        complete resection of high-risk stage III melanoma: Efficacy and<br \/>\n        safety results from the EORTC 1325-MG\/KEYNOTE-054 double-blinded phase<br \/>\n        III trial. In January 2018, Merck and EORTC announced the study met<br \/>\n        the primary endpoint of RFS, showing significant benefit for patients<br \/>\n        with resected stage III melanoma who received KEYTRUDA compared to<br \/>\n        placebo. Abstract #CT001. A Eggermont. Plenary Session: Sunday, April<br \/>\n        15, 9:30 a.m.-12:15 p.m. CDT.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <b>KEYNOTE-040:<\/b> Updated survival results of the KEYNOTE-040 study<br \/>\n        of pembrolizumab vs standard-of-care chemotherapy for recurrent or<br \/>\n        metastatic head and neck squamous cell carcinoma. Updated OS results<br \/>\n        will be presented at AACR. Abstract #CT115. D Souli\u00e8res.<br \/>\n        Minisymposium: Monday, April 16, 3:00-5:00 p.m. CDT.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <b>Merck\u2019s Early Pipeline:<\/b> Combining STING Agonists with an<br \/>\n        Anti-PD-1 Antagonist results in Marked AntiTumor Activity in<br \/>\n        Immune-Excluded Tumors. MK-1454, Merck\u2019s investigational STING<br \/>\n        (stimulator of interferon genes) agonist, is currently being evaluated<br \/>\n        in a phase 1 study as monotherapy and in combination with KEYTRUDA in<br \/>\n        patients with advanced solid tumors and lymphomas. Abstract #4721\/24.<br \/>\n        S Perera. Poster Presentation: Tuesday, April 17, 1:00-5:00 p.m. CDT.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <b>OlympiAD:<\/b> OlympiAD final overall survival: Olaparib versus<br \/>\n        chemotherapy treatment of physician\u2019s choice (TPC) in patients with<br \/>\n        HER2-negative metastatic breast cancer (mBC) and a germline <i>BRCA<\/i><br \/>\n        mutation (g<i>BRCA<\/i>m). Abstract #CT038. M Robson. Minisymposium:<br \/>\n        Sunday, April 15, 3:00-5:00 p.m. CDT.\n      <\/li>\n<\/ul>\n<p>\n      Additional data to be presented for KEYTRUDA (pembrolizumab) and from<br \/>\n      Merck\u2019s collaboration with AstraZeneca for LYNPARZA (olaparib) include:\n    <\/p>\n<p>\n      <span class=\"bwuline\"><br \/>\n<b>Additional KEYTRUDA Data at AACR<\/b><br \/>\n<\/span>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Minisymposium: Safety, efficacy, and immune correlates of alternative<br \/>\n        doses and schedules of entinostat combined with pembrolizumab in<br \/>\n        patients with advanced solid tumors &#8211; results from SNDX-275-0141 Phase<br \/>\n        I trial. AW Tolcher.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Minisymposium: Biomarkers predictive of response to pembrolizumab in<br \/>\n        head and neck cancer (HNSCC). TY Seiwert.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Minisymposium: Effect of JAK\/STAT or PI3K\u03b4 plus PD-1 inhibition on the<br \/>\n        tumor microenvironment: Biomarker results from a phase 1b study in<br \/>\n        patients with advanced solid tumors. J.M. Kirkwood.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Poster Presentation: Durability of responses to the combination of<br \/>\n        SD-101 and pembrolizumab in advanced metastatic melanoma: Results of a<br \/>\n        phase 1b, multicenter study. A Ribas.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Poster Presentation: Phase Ib\/II, open-label, multicenter study of<br \/>\n        intratumoral SD-101 in combination with pembrolizumab in anti-PD-1<br \/>\n        treatment-na\u00efve patients with recurrent or metastatic head and neck<br \/>\n        squamous cell carcinoma (HNSCC). E Cohen.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Poster Presentation: Imprime PGG, a soluble yeast \u03b2-glucan PAMP, in<br \/>\n        combination with Pembrolizumab induces infiltration and activation of<br \/>\n        both innate and adaptive immune cells within tumor sites in melanoma<br \/>\n        and triple-negative breast cancer (TNBC) patients. MT Uhlik.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Poster Presentation: Comprehensive investigation of Programmed Death<br \/>\n        Receptor Ligand 1 (PD-L1) Expression and Associated Molecular Features<br \/>\n        in Gastric Cancer patients. X Liu.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Poster Presentation: Molecular Biomarker Study of Programmed Death<br \/>\n        Receptor Ligand 1 (PD-L1) in Korean Patients with Lung Adenocarcinoma.<br \/>\n        X Liu.\n      <\/li>\n<\/ul>\n<p>\n      <span class=\"bwuline\"><br \/>\n<b>Additional LYNPARZA Data at AACR<\/b><br \/>\n<\/span>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Poster Presentation: A two-stage Simon Design phase II study for<br \/>\n        NOn-BRCA metastatic BReast cancer (MBC) patients with homologous<br \/>\n        recombination deficiency treated with OLAparib single agent. (NOBROLA<br \/>\n        study). E Aguirre.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Poster Presentation: Testing a combination of AKT inhibitor (AZD5363)<br \/>\n        with PARP inhibitor Olaparib plus Carboplatin in TNBC. JH Carlson.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Poster Presentation: Patient derived ovarian cancer xenograft (OC-PDX)<br \/>\n        to study the response of the PARP inhibitor olaparib. F Bizzaro.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Poster Presentation: Adaptive oncology phase 1 study of first-in-class<br \/>\n        inhibitor of ataxia telangiectasia mutated protein kinase (ATM), in<br \/>\n        combination with olaparib. Y Chen.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Poster Presentation: A pre-surgical window of opportunity study to<br \/>\n        investigate the biomarker effects of DNA damage response (DDR) agents<br \/>\n        in patients (pts) with Head and Neck Squamous Cell Carcinoma (HNSCC).<br \/>\n        U Duvvuri.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Poster Presentation: The PARP inhibitor olaparib is synergistic with<br \/>\n        the ATR inhibitor AZD6738 in ATM deficient cancer cells. R Lloyd.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Poster Session: A head-to-head comparison of the properties of five<br \/>\n        clinical PARP inhibitors identifies new insights that can explain both<br \/>\n        the observed clinical efficacy and safety profiles. E Leo.\n      <\/li>\n<\/ul>\n<p>\n      For more information, including a complete list of abstract titles,<br \/>\n      please see the AACR program at&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.abstractsonline.com%2Fpp8%2F%23%21%2F4562&amp;esheet=51773641&amp;newsitemid=20180314006245&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.abstractsonline.com%2Fpp8%2F%23%21%2F4562&amp;index=1&amp;md5=b35d420772db9fb1be793c50bddf0288\" rel=\"nofollow\">http:\/\/www.abstractsonline.com\/pp8\/#!\/4562<\/a>.\n    <\/p>\n<p>\n      <b>Merck Investor Event:<\/b> Merck will hold an investor event in<br \/>\n      conjunction with the 2018 AACR Annual Meeting on Monday, April 16 at<br \/>\n      6:45 p.m. CDT (7:45 p.m. EDT).&nbsp;Those unable to attend in person will be<br \/>\n      able to listen to a live audio webcast of the presentation. Details of<br \/>\n      the event to be provided at a date closer to the event at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Finvestors.merck.com%2Fhome%2Fdefault.aspx&amp;esheet=51773641&amp;newsitemid=20180314006245&amp;lan=en-US&amp;anchor=http%3A%2F%2Finvestors.merck.com%2Fhome%2Fdefault.aspx&amp;index=2&amp;md5=3483b367c25532d20950055a4ccba8e3\" rel=\"nofollow\">http:\/\/investors.merck.com\/home\/default.aspx<\/a>.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae&nbsp;<\/b><br \/>\n<\/sup><br \/>\n<b>(pembrolizumab)<br \/>\n      Injection 100mg<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of<br \/>\n      the body\u2019s immune system to help detect and fight tumor cells. KEYTRUDA<br \/>\n      is a humanized monoclonal antibody that blocks the interaction between<br \/>\n      PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes<br \/>\n      which may affect both tumor cells and healthy cells.\n    <\/p>\n<p>\n      Merck has the industry\u2019s largest immuno-oncology clinical research<br \/>\n      program, which currently involves more than 700 trials studying KEYTRUDA<br \/>\n      across a wide variety of cancers and treatment settings. The KEYTRUDA<br \/>\n      clinical program seeks to understand the role of KEYTRUDA across cancers<br \/>\n      and the factors that may predict a patient\u2019s likelihood of benefitting<br \/>\n      from treatment with KEYTRUDA, including exploring several different<br \/>\n      biomarkers.\n    <\/p>\n<p>\n      <b>KEYTRUDA (pembrolizumab) Indications and Dosing<\/b>\n    <\/p>\n<p>\n      <i>Melanoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma at a fixed dose of 200 mg every three weeks until<br \/>\n      disease progression or unacceptable toxicity.\n    <\/p>\n<p>\n      <i>Lung Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is indicated for the first-line treatment<br \/>\n      of patients with metastatic non-small cell lung cancer (NSCLC) whose<br \/>\n      tumors have high PD-L1 expression [tumor proportion score (TPS) \u226550%] as<br \/>\n      determined by an FDA-approved test, with no EGFR or ALK genomic tumor<br \/>\n      aberrations.\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is also indicated for the treatment of<br \/>\n      patients with metastatic NSCLC whose tumors express PD-L1 (TPS \u22651%) as<br \/>\n      determined by an FDA-approved test, with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA, in combination with pemetrexed and carboplatin, is indicated<br \/>\n      for the first-line treatment of patients with metastatic nonsquamous<br \/>\n      NSCLC. This indication is approved under accelerated approval based on<br \/>\n      tumor response rate and progression-free survival. Continued approval<br \/>\n      for this indication may be contingent upon verification and description<br \/>\n      of clinical benefit in the confirmatory trials.\n    <\/p>\n<p>\n      In metastatic NSCLC, KEYTRUDA (pembrolizumab) is administered at a fixed<br \/>\n      dose of 200 mg every three weeks until disease progression, unacceptable<br \/>\n      toxicity, or up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      When administering KEYTRUDA in combination with chemotherapy, KEYTRUDA<br \/>\n      should be administered prior to chemotherapy when given on the same day.<br \/>\n      See also the Prescribing Information for pemetrexed and carboplatin.\n    <\/p>\n<p>\n      <i>Head and Neck Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic head and neck squamous cell carcinoma (HNSCC) with disease<br \/>\n      progression on or after platinum-containing chemotherapy. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. In HNSCC, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression, unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Classical Hodgkin Lymphoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with refractory classical Hodgkin lymphoma (cHL), or who have relapsed<br \/>\n      after three or more prior lines of therapy. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and durability<br \/>\n      of response. Continued approval for this indication may be contingent<br \/>\n      upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials. In adults with cHL, KEYTRUDA is administered at a<br \/>\n      fixed dose of 200 mg every three weeks until disease progression or<br \/>\n      unacceptable toxicity, or up to 24 months in patients without disease<br \/>\n      progression. In pediatric patients with cHL, KEYTRUDA is administered at<br \/>\n      a dose of 2 mg\/kg (up to a maximum of 200 mg) every three weeks until<br \/>\n      disease progression or unacceptable toxicity, or up to 24 months in<br \/>\n      patients without disease progression.\n    <\/p>\n<p>\n      <i>Urothelial Carcinoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma who are not eligible for<br \/>\n      cisplatin-containing chemotherapy. This indication is approved under<br \/>\n      accelerated approval based on tumor response rate and duration of<br \/>\n      response. Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials.\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) is also indicated for the treatment of patients<br \/>\n      with locally advanced or metastatic urothelial carcinoma who have<br \/>\n      disease progression during or following platinum-containing chemotherapy<br \/>\n      or within 12 months of neoadjuvant or adjuvant treatment with<br \/>\n      platinum-containing chemotherapy.\n    <\/p>\n<p>\n      In locally advanced or metastatic urothelial carcinoma, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Microsatellite Instability-High (MSI-H) Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with unresectable or metastatic microsatellite instability-high (MSI-H)<br \/>\n      or mismatch repair deficient (dMMR)\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        solid tumors that have progressed following prior treatment and who<br \/>\n        have no satisfactory alternative treatment options, or\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        colorectal cancer that has progressed following treatment with<br \/>\n        fluoropyrimidine, oxaliplatin, and irinotecan.\n      <\/li>\n<\/ul>\n<p>\n      This indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. The safety and<br \/>\n      effectiveness of KEYTRUDA in pediatric patients with MSI-H central<br \/>\n      nervous system cancers have not been established.\n    <\/p>\n<p>\n      In adult patients with MSI-H cancer, KEYTRUDA is administered at a fixed<br \/>\n      dose of 200 mg every three weeks until disease progression, unacceptable<br \/>\n      toxicity, or up to 24 months in patients without disease progression. In<br \/>\n      children with MSI-H cancer, KEYTRUDA is administered at a dose of 2<br \/>\n      mg\/kg (up to a maximum of 200 mg) every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Gastric Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent<br \/>\n      locally advanced or metastatic gastric or gastroesophageal junction<br \/>\n      (GEJ) adenocarcinoma whose tumors express PD-L1 [Combined Positive Score<br \/>\n      (CPS) \u22651] as determined by an FDA-approved test, with disease<br \/>\n      progression on or after two or more prior lines of therapy including<br \/>\n      fluoropyrimidine- and platinum-containing chemotherapy and if<br \/>\n      appropriate, HER2\/neu-targeted therapy. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and durability<br \/>\n      of response. Continued approval for this indication may be contingent<br \/>\n      upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials. The recommended dose of KEYTRUDA (pembrolizumab) is<br \/>\n      200 mg every three weeks until disease progression, unacceptable<br \/>\n      toxicity, or up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup>&nbsp;<b>(pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated pneumonitis, including fatal cases.<br \/>\n      Pneumonitis occurred in 94 (3.4%) of 2799 patients receiving KEYTRUDA,<br \/>\n      including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4 (0.3%), and 5 (0.1%)<br \/>\n      pneumonitis, and occurred more frequently in patients with a history of<br \/>\n      prior thoracic radiation (6.9%) compared to those without (2.9%).<br \/>\n      Monitor patients for signs and symptoms of pneumonitis. Evaluate<br \/>\n      suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 or<br \/>\n      recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 48<br \/>\n      (1.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.4%), 3<br \/>\n      (1.1%), and 4 (&lt;0.1%) colitis. Monitor patients for signs and symptoms<br \/>\n      of colitis. Administer corticosteroids for Grade 2 or greater colitis.<br \/>\n      Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 colitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred in 19<br \/>\n      (0.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.4%), and 4 (&lt;0.1%) hepatitis. Monitor patients for changes in liver<br \/>\n      function. Administer corticosteroids for Grade 2 or greater hepatitis<br \/>\n      and, based on severity of liver enzyme elevations, withhold or<br \/>\n      discontinue KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA can cause hypophysitis. Hypophysitis occurred in 17 (0.6%) of<br \/>\n      2799 patients receiving KEYTRUDA, including Grade 2 (0.2%), 3 (0.3%),<br \/>\n      and 4 (&lt;0.1%) hypophysitis. Monitor patients for signs and symptoms of<br \/>\n      hypophysitis (including hypopituitarism and adrenal insufficiency).<br \/>\n      Administer corticosteroids and hormone replacement as clinically<br \/>\n      indicated. Withhold KEYTRUDA for Grade 2; withhold or discontinue for<br \/>\n      Grade 3 or 4 hypophysitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause thyroid disorders, including hyperthyroidism,<br \/>\n      hypothyroidism, and thyroiditis. Hyperthyroidism occurred in 96 (3.4%)<br \/>\n      of 2799 patients receiving KEYTRUDA, including Grade 2 (0.8%) and 3<br \/>\n      (0.1%) hyperthyroidism. Hypothyroidism occurred in 237 (8.5%) of 2799<br \/>\n      patients receiving KEYTRUDA, including Grade 2 (6.2%) and 3 (0.1%)<br \/>\n      hypothyroidism. The incidence of new or worsening hypothyroidism was<br \/>\n      higher in patients with HNSCC, occurring in 28 (15%) of 192 patients<br \/>\n      with HNSCC, including Grade 3 (0.5%) hypothyroidism. Thyroiditis<br \/>\n      occurred in 16 (0.6%) of 2799 patients receiving KEYTRUDA<br \/>\n      (pembrolizumab), including Grade 2 (0.3%) thyroiditis. Monitor patients<br \/>\n      for changes in thyroid function (at the start of treatment, periodically<br \/>\n      during treatment, and as indicated based on clinical evaluation) and for<br \/>\n      clinical signs and symptoms of thyroid disorders. Administer replacement<br \/>\n      hormones for hypothyroidism and manage hyperthyroidism with thionamides<br \/>\n      and beta-blockers as appropriate. Withhold or discontinue KEYTRUDA for<br \/>\n      Grade 3 or 4 hyperthyroidism.\n    <\/p>\n<p>\n      KEYTRUDA can cause type 1 diabetes mellitus, including diabetic<br \/>\n      ketoacidosis, which have been reported in 6 (0.2%) of 2799 patients.<br \/>\n      Monitor patients for hyperglycemia or other signs and symptoms of<br \/>\n      diabetes. Administer insulin for type 1 diabetes, and withhold KEYTRUDA<br \/>\n      and administer antihyperglycemics in patients with severe hyperglycemia.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated nephritis. Nephritis occurred in 9<br \/>\n      (0.3%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.1%), and 4 (&lt;0.1%) nephritis. Monitor patients for changes in renal<br \/>\n      function. Administer corticosteroids for Grade 2 or greater nephritis.<br \/>\n      Withhold KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for<br \/>\n      Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Immune-mediated rashes, including Stevens-Johnson syndrome (SJS), toxic<br \/>\n      epidermal necrolysis (TEN) (some cases with fatal outcome), exfoliative<br \/>\n      dermatitis, and bullous pemphigoid, can occur. Monitor patients for<br \/>\n      suspected severe skin reactions and based on the severity of the adverse<br \/>\n      reaction, withhold or permanently discontinue KEYTRUDA and administer<br \/>\n      corticosteroids. For signs or symptoms of SJS or TEN, withhold KEYTRUDA<br \/>\n      and refer the patient for specialized care for assessment and treatment.<br \/>\n      If SJS or TEN is confirmed, permanently discontinue KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA can cause other clinically important immune-mediated adverse<br \/>\n      reactions. These immune-mediated reactions may occur in any organ<br \/>\n      system. For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement to Grade 1 or less, initiate<br \/>\n      corticosteroid taper and continue to taper over at least 1 month. Based<br \/>\n      on limited data from clinical studies in patients whose immune-related<br \/>\n      adverse reactions could not be controlled with corticosteroid use,<br \/>\n      administration of other systemic immunosuppressants can be considered.<br \/>\n      Resume KEYTRUDA when the adverse reaction remains at Grade 1 or less<br \/>\n      following corticosteroid taper. Permanently discontinue KEYTRUDA<br \/>\n      (pembrolizumab) for any Grade 3 immune-mediated adverse reaction that<br \/>\n      recurs and for any life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 2799 patients:<br \/>\n      arthritis (1.5%), uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia<br \/>\n      gravis, vasculitis, pancreatitis, hemolytic anemia, and partial seizures<br \/>\n      arising in a patient with inflammatory foci in brain parenchyma. In<br \/>\n      addition, myelitis and myocarditis were reported in other clinical<br \/>\n      trials, including classical Hodgkin lymphoma, and postmarketing use.\n    <\/p>\n<p>\n      Solid organ transplant rejection has been reported in postmarketing use<br \/>\n      of KEYTRUDA. Treatment with KEYTRUDA may increase the risk of rejection<br \/>\n      in solid organ transplant recipients. Consider the benefit of treatment<br \/>\n      with KEYTRUDA vs the risk of possible organ rejection in these patients.\n    <\/p>\n<p>\n      KEYTRUDA can cause severe or life-threatening infusion-related<br \/>\n      reactions, including hypersensitivity and anaphylaxis, which have been<br \/>\n      reported in 6 (0.2%) of 2799 patients. Monitor patients for signs and<br \/>\n      symptoms of infusion-related reactions, including rigors, chills,<br \/>\n      wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever.<br \/>\n      For Grade 3 or 4 reactions, stop infusion and permanently discontinue<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      Immune-mediated complications, including fatal events, occurred in<br \/>\n      patients who underwent allogeneic hematopoietic stem cell<br \/>\n      transplantation (HSCT) after being treated with KEYTRUDA. Of 23 patients<br \/>\n      with cHL who proceeded to allogeneic HSCT after treatment with KEYTRUDA<br \/>\n      on any trial, 6 patients (26%) developed graft-versus-host disease<br \/>\n      (GVHD), one of which was fatal, and 2 patients (9%) developed severe<br \/>\n      hepatic veno-occlusive disease (VOD) after reduced-intensity<br \/>\n      conditioning, one of which was fatal. Cases of fatal hyperacute GVHD<br \/>\n      after allogeneic HSCT have also been reported in patients with lymphoma<br \/>\n      who received a PD-1 receptor\u2013blocking antibody before transplantation.\n    <\/p>\n<p>\n      These complications may occur despite intervening therapy between PD-1<br \/>\n      blockade and allogeneic HSCT. Follow patients closely for early evidence<br \/>\n      of transplant-related complications such as hyperacute GVHD, severe<br \/>\n      (Grade 3 to 4) acute GVHD, steroid-requiring febrile syndrome, hepatic<br \/>\n      VOD, and other immune-mediated adverse reactions, and intervene promptly.\n    <\/p>\n<p>\n      In clinical trials in patients with multiple myeloma, the addition of<br \/>\n      KEYTRUDA to a thalidomide analogue plus dexamethasone resulted in<br \/>\n      increased mortality. Treatment of these patients with a PD-1 or PD-L1<br \/>\n      blocking antibody in this combination is not recommended outside of<br \/>\n      controlled clinical trials.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA (pembrolizumab) can cause<br \/>\n      fetal harm when administered to a pregnant woman. If used during<br \/>\n      pregnancy, or if the patient becomes pregnant during treatment, apprise<br \/>\n      the patient of the potential hazard to a fetus. Advise females of<br \/>\n      reproductive potential to use highly effective contraception during<br \/>\n      treatment and for 4 months after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      In KEYNOTE-006, KEYTRUDA was discontinued due to adverse reactions in 9%<br \/>\n      of 555 patients with advanced melanoma; adverse reactions leading to<br \/>\n      discontinuation in more than one patient were colitis (1.4%), autoimmune<br \/>\n      hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy (0.4%), and<br \/>\n      cardiac failure (0.4%). Adverse reactions leading to interruption of<br \/>\n      KEYTRUDA occurred in 21% of patients; the most common (\u22651%) was diarrhea<br \/>\n      (2.5%). The most common adverse reactions with KEYTRUDA vs ipilimumab<br \/>\n      were fatigue (28% vs 28%), diarrhea (26% with KEYTRUDA), rash (24% vs<br \/>\n      23%), and nausea (21% with KEYTRUDA). Corresponding incidence rates are<br \/>\n      listed for ipilimumab only for those adverse reactions that occurred at<br \/>\n      the same or lower rate than with KEYTRUDA.\n    <\/p>\n<p>\n      In KEYNOTE-010, KEYTRUDA monotherapy was discontinued due to adverse<br \/>\n      reactions in 8% of 682 patients with metastatic NSCLC. The most common<br \/>\n      adverse event resulting in permanent discontinuation of KEYTRUDA was<br \/>\n      pneumonitis (1.8%). Adverse reactions leading to interruption of<br \/>\n      KEYTRUDA occurred in 23% of patients; the most common (\u22651%) were<br \/>\n      diarrhea (1%), fatigue (1.3%), pneumonia (1%), liver enzyme elevation<br \/>\n      (1.2%), decreased appetite (1.3%), and pneumonitis (1%). The most common<br \/>\n      adverse reactions (occurring in at least 20% of patients and at a higher<br \/>\n      incidence than with docetaxel) were decreased appetite (25% vs 23%),<br \/>\n      dyspnea (23% vs 20%), and nausea (20% vs 18%).\n    <\/p>\n<p>\n      In KEYNOTE-021(G1), when KEYTRUDA was administered in combination with<br \/>\n      carboplatin and pemetrexed (carbo\/pem) in advanced nonsquamous NSCLC,<br \/>\n      KEYTRUDA was discontinued in 10% of 59 patients. The most common adverse<br \/>\n      reaction resulting in discontinuation of KEYTRUDA (\u22652%) was acute kidney<br \/>\n      injury (3.4%). Adverse reactions leading to interruption of KEYTRUDA<br \/>\n      occurred in 39% of patients; the most common (\u22652%) were fatigue (8%),<br \/>\n      neutrophil count decreased (8%), anemia (5%), dyspnea (3.4%), and<br \/>\n      pneumonitis (3.4%). The most common adverse reactions (\u226520%) with<br \/>\n      KEYTRUDA compared to carbo\/pem alone were fatigue (71% vs 50%), nausea<br \/>\n      (68% vs 56%), constipation (51% vs 37%), rash (42% vs 21%), vomiting<br \/>\n      (39% vs 27%), dyspnea (39% vs 21%), diarrhea (37% vs 23%), decreased<br \/>\n      appetite (31% vs 23%), headache (31% vs 16%), cough (24% vs 18%),<br \/>\n      dizziness (24% vs 16%), insomnia (24% vs 15%), pruritus (24% vs 4.8%),<br \/>\n      peripheral edema (22% vs 18%), dysgeusia (20% vs 11%), alopecia (20% vs<br \/>\n      3.2%), upper respiratory tract infection (20% vs 3.2%), and arthralgia<br \/>\n      (15% vs 24%). This study was not designed to demonstrate a statistically<br \/>\n      significant difference in adverse reaction rates for KEYTRUDA<br \/>\n      (pembrolizumab) as compared to carbo\/pem alone for any specified adverse<br \/>\n      reaction.\n    <\/p>\n<p>\n      In KEYNOTE-012, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      17% of 192 patients with HNSCC. Serious adverse reactions occurred in<br \/>\n      45% of patients. The most frequent serious adverse reactions reported in<br \/>\n      at least 2% of patients were pneumonia, dyspnea, confusional state,<br \/>\n      vomiting, pleural effusion, and respiratory failure. The most common<br \/>\n      adverse reactions (reported in at least 20% of patients) were fatigue,<br \/>\n      decreased appetite, and dyspnea. Adverse reactions occurring in patients<br \/>\n      with HNSCC were generally similar to those occurring in patients with<br \/>\n      melanoma or NSCLC, with the exception of increased incidences of facial<br \/>\n      edema (10% all Grades; 2.1% Grades 3 or 4) and new or worsening<br \/>\n      hypothyroidism.\n    <\/p>\n<p>\n      In KEYNOTE-087, KEYTRUDA was discontinued due to adverse reactions in 5%<br \/>\n      of 210 patients with cHL, and treatment was interrupted due to adverse<br \/>\n      reactions in 26% of patients. Fifteen percent (15%) of patients had an<br \/>\n      adverse reaction requiring systemic corticosteroid therapy. Serious<br \/>\n      adverse reactions occurred in 16% of patients. The most frequent serious<br \/>\n      adverse reactions (\u22651%) included pneumonia, pneumonitis, pyrexia,<br \/>\n      dyspnea, GVHD, and herpes zoster. Two patients died from causes other<br \/>\n      than disease progression; one from GVHD after subsequent allogeneic HSCT<br \/>\n      and one from septic shock. The most common adverse reactions (occurring<br \/>\n      in \u226520% of patients) were fatigue (26%), pyrexia (24%), cough (24%),<br \/>\n      musculoskeletal pain (21%), diarrhea (20%), and rash (20%).\n    <\/p>\n<p>\n      In KEYNOTE-052, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      11% of 370 patients with locally advanced or metastatic urothelial<br \/>\n      carcinoma. The most common adverse reactions (in \u226520% of patients) were<br \/>\n      fatigue (38%), musculoskeletal pain (24%), decreased appetite (22%),<br \/>\n      constipation (21%), rash (21%), and diarrhea (20%). Eighteen patients<br \/>\n      (5%) died from causes other than disease progression. Five patients<br \/>\n      (1.4%) who were treated with KEYTRUDA experienced sepsis which led to<br \/>\n      death, and 3 patients (0.8%) experienced pneumonia which led to death.<br \/>\n      Adverse reactions leading to interruption of KEYTRUDA occurred in 22% of<br \/>\n      patients; the most common (\u22651%) were liver enzyme increase, diarrhea,<br \/>\n      urinary tract infection, acute kidney injury, fatigue, joint pain, and<br \/>\n      pneumonia. Serious adverse reactions occurred in 42% of patients, the<br \/>\n      most frequent (\u22652%) of which were urinary tract infection, hematuria,<br \/>\n      acute kidney injury, pneumonia, and urosepsis.\n    <\/p>\n<p>\n      In KEYNOTE-045, KEYTRUDA was discontinued due to adverse reactions in 8%<br \/>\n      of 266 patients with locally advanced or metastatic urothelial<br \/>\n      carcinoma. The most common adverse reaction resulting in permanent<br \/>\n      discontinuation of KEYTRUDA (pembrolizumab) was pneumonitis (1.9%).<br \/>\n      Adverse reactions leading to interruption of KEYTRUDA occurred in 20% of<br \/>\n      patients; the most common (\u22651%) were urinary tract infection (1.5%),<br \/>\n      diarrhea (1.5%), and colitis (1.1%). The most common adverse reactions<br \/>\n      (\u226520%) in patients who received KEYTRUDA vs those who received<br \/>\n      chemotherapy were fatigue (38% vs 56%), musculoskeletal pain (32% vs<br \/>\n      27%), pruritus (23% vs 6%), decreased appetite (21% vs 21%), nausea (21%<br \/>\n      vs 29%), and rash (20% vs 13%). Serious adverse reactions occurred in<br \/>\n      39% of KEYTRUDA-treated patients, the most frequent (\u22652%) of which were<br \/>\n      urinary tract infection, pneumonia, anemia, and pneumonitis.\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA and for 4 months after the final dose.\n    <\/p>\n<p>\n      There is limited experience in pediatric patients. In a study, 40<br \/>\n      pediatric patients (16 children aged 2 years to younger than 12 years<br \/>\n      and 24 adolescents aged 12 years to 18 years) with advanced melanoma,<br \/>\n      lymphoma, or PD-L1\u2013positive advanced, relapsed, or refractory solid<br \/>\n      tumors were administered KEYTRUDA 2 mg\/kg every 3 weeks. Patients<br \/>\n      received KEYTRUDA for a median of 3 doses (range 1\u201317 doses), with 34<br \/>\n      patients (85%) receiving KEYTRUDA for 2 doses or more. The safety<br \/>\n      profile in these pediatric patients was similar to that seen in adults<br \/>\n      treated with KEYTRUDA. Toxicities that occurred at a higher rate (\u226515%<br \/>\n      difference) in these patients when compared to adults under 65 years of<br \/>\n      age were fatigue (45%), vomiting (38%), abdominal pain (28%),<br \/>\n      hypertransaminasemia (28%), and hyponatremia (18%).\n    <\/p>\n<p>\n      <b>About LYNPARZA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (olaparib)<\/b>\n    <\/p>\n<p>\n      LYNPARZA is the first FDA-approved oral poly ADP-ribose polymerase<br \/>\n      (PARP) inhibitor and the first targeted treatment to potentially exploit<br \/>\n      DNA damage response (DDR) pathway deficiencies, such as <i>BRCA<\/i><br \/>\n      mutations, to preferentially kill cancer cells. Specifically, <i>in vitro<\/i><br \/>\n      studies have shown that LYNPARZA-induced cytotoxicity may involve<br \/>\n      inhibition of PARP enzymatic activity and increased formation of<br \/>\n      PARP-DNA complexes, resulting in DNA damage and cancer cell death.\n    <\/p>\n<p>\n      <b>Indications for LYNPARZA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (olaparib) in the<br \/>\n      U.S.<\/b>\n    <\/p>\n<p>\n      LYNPARZA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated:\n    <\/p>\n<p>\n      For the maintenance treatment of adult patients with recurrent<br \/>\n      epithelial ovarian, fallopian tube, or primary peritoneal cancer, who<br \/>\n      are in complete or partial response to platinum-based chemotherapy.\n    <\/p>\n<p>\n      For the treatment of adult patients with deleterious or suspected<br \/>\n      deleterious germline&nbsp;<i>BRCA-<\/i>mutated (<i>gBRCAm<\/i>) advanced<br \/>\n      ovarian cancer who have been treated with 3 or more prior lines of<br \/>\n      chemotherapy. Select patients for therapy based on an FDA-approved<br \/>\n      companion diagnostic for LYNPARZA (olaparib).\n    <\/p>\n<p>\n      In patients with deleterious or suspected deleterious&nbsp;<i>gBRCAm,&nbsp;<\/i>human<br \/>\n      epidermal growth factor receptor 2 (HER2)-negative metastatic breast<br \/>\n      cancer who have previously been treated with chemotherapy in the<br \/>\n      neoadjuvant, adjuvant or metastatic setting. Patients with hormone<br \/>\n      receptor (HR)-positive breast cancer should have been treated with a<br \/>\n      prior endocrine therapy or be considered inappropriate for endocrine<br \/>\n      treatment. Select patients for therapy based on an FDA-approved<br \/>\n      companion diagnostic for LYNPARZA.\n    <\/p>\n<p>\n      <b>Important Safety Information for LYNPARZA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b><br \/>\n      (olaparib)<\/b>\n    <\/p>\n<p>\n      <b>Contraindications<\/b>\n    <\/p>\n<p>\n      There are no contraindications for LYNPARZA.\n    <\/p>\n<p>\n      <b>Warnings and Precautions<\/b>\n    <\/p>\n<p>\n      <b>Myelodysplastic Syndrome\/Acute Myeloid Leukemia (MDS\/AML):<\/b>&nbsp;Occurred<br \/>\n      in &lt;1.5% of patients exposed to LYNPARZA monotherapy, and the majority<br \/>\n      of events had a fatal outcome. The duration of therapy in patients who<br \/>\n      developed secondary MDS\/AML varied from &lt;6 months to &gt;2 years. All of<br \/>\n      these patients had previous chemotherapy with platinum agents and\/or<br \/>\n      other DNA-damaging agents, including radiotherapy, and some also had a<br \/>\n      history of more than one primary malignancy or of bone marrow dysplasia.\n    <\/p>\n<p>\n      Do not start LYNPARZA until patients have recovered from hematological<br \/>\n      toxicity caused by previous chemotherapy (\u2264Grade 1). Monitor complete<br \/>\n      blood count for cytopenia at baseline and monthly thereafter for<br \/>\n      clinically significant changes during treatment. For prolonged<br \/>\n      hematological toxicities, interrupt LYNPARZA and monitor blood count<br \/>\n      weekly until recovery.\n    <\/p>\n<p>\n      If the levels have not recovered to Grade 1 or less after 4 weeks, refer<br \/>\n      the patient to a hematologist for further investigations, including bone<br \/>\n      marrow analysis and blood sample for cytogenetics. Discontinue LYNPARZA<br \/>\n      if MDS\/AML is confirmed.\n    <\/p>\n<p>\n      <b>Pneumonitis:<\/b>&nbsp;Occurred in &lt;1% of patients exposed to LYNPARZA<br \/>\n      (olaparib), and some cases were fatal. If patients present with new or<br \/>\n      worsening respiratory symptoms such as dyspnea, cough, and fever, or a<br \/>\n      radiological abnormality occurs, interrupt LYNPARZA treatment and<br \/>\n      initiate prompt investigation. Discontinue LYNPARZA if pneumonitis is<br \/>\n      confirmed and treat patient appropriately.\n    <\/p>\n<p>\n      <b>Embryo-Fetal Toxicity:<\/b>&nbsp;Based on its mechanism of action and<br \/>\n      findings in animals, LYNPARZA can cause fetal harm. A pregnancy test is<br \/>\n      recommended for females of reproductive potential prior to initiating<br \/>\n      treatment. Advise females of reproductive potential of the potential<br \/>\n      risk to a fetus and to use effective contraception during treatment and<br \/>\n      for 6 months following the last dose.<i>&nbsp;<\/i>Advise male patients<br \/>\n      with female partners of reproductive potential or who are pregnant to<br \/>\n      use effective contraception during treatment and for 3 months following<br \/>\n      the last dose of LYNPARZA and to not donate sperm during this time.\n    <\/p>\n<p>\n      <b>Adverse Reactions\u2014Maintenance Setting<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226520% of patients in<br \/>\n      clinical trials of LYNPARZA (olaparib) in the&nbsp;maintenance<br \/>\n      setting&nbsp;for&nbsp;SOLO-2: nausea (76%), fatigue (including asthenia) (66%),<br \/>\n      anemia (44%), vomiting (37%), nasopharyngitis\/upper respiratory tract<br \/>\n      infection (URI)\/influenza (36%), diarrhea (33%), arthralgia\/myalgia<br \/>\n      (30%), dysgeusia (27%), headache (26%), decreased appetite (22%), and<br \/>\n      stomatitis (20%).\n    <\/p>\n<p>\n      Study 19:&nbsp;nausea (71%), fatigue (including asthenia) (63%), vomiting<br \/>\n      (35%), diarrhea (28%), anemia (23%), respiratory tract infection (22%),<br \/>\n      constipation (22%), headache (21%), and decreased appetite (21%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in<br \/>\n      clinical trials of LYNPARZA in the&nbsp;maintenance setting (SOLO-2\/Study 19)<br \/>\n      were: increase in mean corpuscular volume (89%\/82%), decrease in<br \/>\n      hemoglobin (83%\/82%), decrease in leukocytes (69%\/58%), decrease in<br \/>\n      lymphocytes (67%\/52%), decrease in absolute neutrophil count (51%\/47%),<br \/>\n      increase in serum creatinine (44%\/45%), and decrease in platelets<br \/>\n      (42%\/36%).\n    <\/p>\n<p>\n      <b>Adverse Reactions\u2014Advanced g<i>BRCA<\/i>m Ovarian Cancer<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226520% of patients in<br \/>\n      clinical trials of LYNPARZA for&nbsp;advanced g<i>BRCA<\/i>m ovarian<br \/>\n      cancer after 3 or more lines of chemotherapy&nbsp;(pooled from 6 studies)<br \/>\n      were: fatigue (including asthenia) (66%), nausea (64%), vomiting (43%),<br \/>\n      anemia (34%), diarrhea (31%), nasopharyngitis\/upper respiratory tract<br \/>\n      infection (URI) (26%), dyspepsia (25%), myalgia (22%), decreased<br \/>\n      appetite (22%), and arthralgia\/musculoskeletal pain (21%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in<br \/>\n      clinical trials of LYNPARZA (olaparib) for&nbsp;advanced g<i>BRCA<\/i>m<br \/>\n      ovarian cancer&nbsp;(pooled from 6 studies) were: decrease in hemoglobin<br \/>\n      (90%), increase in mean corpuscular volume (57%), decrease in<br \/>\n      lymphocytes (56%), increase in serum creatinine (30%), decrease in<br \/>\n      platelets (30%), and decrease in absolute neutrophil count (25%).\n    <\/p>\n<p>\n      <b>Adverse Reactions\u2014g<i>BRCA<\/i>m, HER2-Negative Breast Cancer<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226520% of patients<br \/>\n      in&nbsp;OlympiAD&nbsp;were: nausea (58%), anemia (40%), fatigue (including<br \/>\n      asthenia) (37%), vomiting (30%), neutropenia (27%), respiratory tract<br \/>\n      infection (27%), leukopenia (25%), diarrhea (21%), and headache (20%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients<br \/>\n      in&nbsp;OlympiAD&nbsp;were: decrease in hemoglobin (82%), decrease in lymphocytes<br \/>\n      (73%), decrease in leukocytes (71%), increase in mean corpuscular volume<br \/>\n      (71%), decrease in absolute neutrophil count (46%), and decrease in<br \/>\n      platelets (33%).\n    <\/p>\n<p>\n      <b>Drug Interactions<\/b>\n    <\/p>\n<p>\n      <b>Anticancer Agents:<\/b>&nbsp;Clinical studies of LYNPARZA in combination<br \/>\n      with other myelosuppressive anticancer agents, including DNA-damaging<br \/>\n      agents, indicate a potentiation and prolongation of myelosuppressive<br \/>\n      toxicity.\n    <\/p>\n<p>\n      <b>CYP3A Inhibitors:<\/b>&nbsp;Avoid concomitant use of strong or moderate<br \/>\n      CYP3A inhibitors. If a strong or moderate CYP3A inhibitor must be<br \/>\n      co-administered, reduce the dose of LYNPARZA. Advise patients to avoid<br \/>\n      grapefruit, grapefruit juice, Seville oranges, and Seville orange juice<br \/>\n      during LYNPARZA treatment.\n    <\/p>\n<p>\n      <b>CYP3A Inducers:<\/b>&nbsp;Avoid concomitant use of strong or moderate CYP3A<br \/>\n      inducers when using LYNPARZA (olaparib). If a moderate inducer cannot be<br \/>\n      avoided, there is a potential for decreased efficacy of LYNPARZA.\n    <\/p>\n<p>\n      <b>Use in Specific Populations<\/b>\n    <\/p>\n<p>\n      <b>Lactation:<\/b>&nbsp;No data are available regarding the presence of<br \/>\n      olaparib in human milk, its effects on the breastfed infant or on milk<br \/>\n      production. Because of the potential for serious adverse reactions in<br \/>\n      the breastfed infant, advise a lactating woman not to breastfeed during<br \/>\n      treatment with LYNPARZA (olaparib) and for 1 month after receiving the<br \/>\n      final dose.\n    <\/p>\n<p>\n      <b>Pediatric Use:<\/b>&nbsp;The safety and efficacy of LYNPARZA have not been<br \/>\n      established in pediatric patients.\n    <\/p>\n<p>\n      <b>Hepatic Impairment:<\/b>&nbsp;No adjustment to the starting dose is<br \/>\n      required in patients with mild hepatic impairment (Child-Pugh<br \/>\n      classification A). There are no data in patients with moderate or severe<br \/>\n      hepatic impairment.\n    <\/p>\n<p>\n      <b>Renal Impairment:<\/b>&nbsp;No adjustment to the starting dose is necessary<br \/>\n      in patients with mild renal impairment (CLcr=51-80 mL\/min). In patients<br \/>\n      with moderate renal impairment (CLcr=31-50 mL\/min), reduce the dose to<br \/>\n      200 mg twice daily. There are no data in patients with severe renal<br \/>\n      impairment or end-stage renal disease (CLcr \u226430 mL\/min).\n    <\/p>\n<p>\n      <b>Dosing and Administration<\/b>\n    <\/p>\n<p>\n      To avoid substitution errors and overdose,&nbsp;<b>do not substitute<br \/>\n      LYNPARZA&nbsp;tablets with LYNPARZA capsules&nbsp;<\/b>on a<br \/>\n      milligram-to-milligram basis due to differences in the dosing and<br \/>\n      bioavailability of each formulation. Recommended tablet dose is 300 mg,<br \/>\n      taken orally twice daily, with or without food. Continue treatment until<br \/>\n      disease progression or unacceptable toxicity. For adverse reactions,<br \/>\n      consider dose interruption or dose reduction.\n    <\/p>\n<p>\n      <b>About the AstraZeneca and Merck Strategic Oncology Collaboration<\/b>\n    <\/p>\n<p>\n      In July 2017, AstraZeneca and Merck (known as MSD outside the United<br \/>\n      States and Canada) announced a global strategic oncology collaboration<br \/>\n      to co-develop and co-commercialize LYNPARZA, the world\u2019s first PARP<br \/>\n      inhibitor, and potential new medicine selumetinib, a MEK inhibitor, for<br \/>\n      multiple cancer types. The collaboration is based on increasing evidence<br \/>\n      that PARP and MEK inhibitors can be combined with PD-L1\/PD-1 inhibitors<br \/>\n      for a range of tumor types. Working together, the companies will jointly<br \/>\n      develop LYNPARZA and selumetinib in combination with other potential new<br \/>\n      medicines and as a monotherapy. Independently, the companies will<br \/>\n      develop LYNPARZA and selumetinib in combination with their respective<br \/>\n      PD-L1 and PD-1 medicines.\n    <\/p>\n<p>\n      <b>Merck\u2019s Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, helping people<br \/>\n      fight cancer is our passion and supporting accessibility to our cancer<br \/>\n      medicines is our commitment. Our focus is on pursuing research in<br \/>\n      immuno-oncology and we are accelerating every step in the journey \u2013 from<br \/>\n      lab to clinic \u2013 to potentially bring new hope to people with cancer.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the fastest-growing development<br \/>\n      programs in the industry. We are currently executing an expansive<br \/>\n      research program evaluating our anti-PD-1 therapy across more than 30<br \/>\n      tumor types. We also continue to strengthen our immuno-oncology<br \/>\n      portfolio through strategic acquisitions and are prioritizing the<br \/>\n      development of several promising immunotherapeutic candidates with the<br \/>\n      potential to improve the treatment of advanced cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51773641&amp;newsitemid=20180314006245&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=3&amp;md5=006508f8f296ef11e55eccbeec1b85cb\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Findex.html&amp;esheet=51773641&amp;newsitemid=20180314006245&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=4&amp;md5=6a5bd1bb4c36024a323dec6adbd92bf7\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and&nbsp;connect with us on&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51773641&amp;newsitemid=20180314006245&amp;lan=en-US&amp;anchor=Twitter&amp;index=5&amp;md5=1fd55538f2f550a55775d3745d9658ea\" rel=\"nofollow\">Twitter<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=51773641&amp;newsitemid=20180314006245&amp;lan=en-US&amp;anchor=Facebook&amp;index=6&amp;md5=bbf4725176cd2b0c06d3fe2e1f93f2a0\" rel=\"nofollow\">Facebook<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=51773641&amp;newsitemid=20180314006245&amp;lan=en-US&amp;anchor=Instagram&amp;index=7&amp;md5=94e6785d5865bde5ca1fb31a6255167b\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51773641&amp;newsitemid=20180314006245&amp;lan=en-US&amp;anchor=YouTube&amp;index=8&amp;md5=3cc2b242bbd4db35e0e9e110cd2ba69d\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51773641&amp;newsitemid=20180314006245&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=9&amp;md5=7e63b71dd9a31dd4775809650d93ec01\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2017 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51773641&amp;newsitemid=20180314006245&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=10&amp;md5=e21e7f601da8324f5602103c03309780\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at <\/b><br \/>\n<br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51773641&amp;newsitemid=20180314006245&amp;lan=en-US&amp;anchor=https%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=11&amp;md5=4b0f22880508eae13704e42bad42d2f5\" rel=\"nofollow\"><br \/>\n<b>https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b><br \/>\n      and <\/b><br \/>\n<br \/>\n<b>Patient Information\/Medication Guide for KEYTRUDA at <\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51773641&amp;newsitemid=20180314006245&amp;lan=en-US&amp;anchor=https%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=12&amp;md5=3f565439af86aaf595a2f78fab26d011\" rel=\"nofollow\"><br \/>\n<b>https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<p>\n      <b>Please see complete Prescribing Information for LYNPARZA (olaparib)<br \/>\n      tablets<\/b><br \/>\n<br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.azpicentral.com%2Flynparza_tb%2Fpi_lynparza_tb.pdf%23page%3D1&amp;esheet=51773641&amp;newsitemid=20180314006245&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.azpicentral.com%2Flynparza_tb%2Fpi_lynparza_tb.pdf%23page%3D1&amp;index=13&amp;md5=527130701172b301c174a489602e7793\" rel=\"nofollow\"><br \/>\n<b>https:\/\/www.azpicentral.com\/lynparza_tb\/pi_lynparza_tb.pdf#page=1<\/b><br \/>\n<\/a><br \/>\n<b><br \/>\n      and complete <\/b><br \/>\n<br \/>\n<b>Prescribing Information for LYNPARZA capsules,<\/b><br \/>\n<br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.azpicentral.com%2FLynparza%2Fpi_lynparza.pdf%23page%3D1&amp;esheet=51773641&amp;newsitemid=20180314006245&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.azpicentral.com%2FLynparza%2Fpi_lynparza.pdf%23page%3D1&amp;index=14&amp;md5=64758ac75aef32f9fa7d93b0bb4835dc\" rel=\"nofollow\"><br \/>\n<b>https:\/\/www.azpicentral.com\/Lynparza\/pi_lynparza.pdf#page=1<\/b><br \/>\n<\/a><br \/>\n<b><br \/>\n      including Patient Information (Medication Guides).<\/b>\n    <\/p>\n<p>\n      ALIMTA<sup>\u00ae<\/sup>&nbsp;is a registered trademark of Eli Lilly and Company.\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20180314006245r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Courtney        Ronaldo, 908-740-6132<br \/>or<br \/>Investors:<br \/>Teri Loxam,        908-740-1986<br \/>or<br \/>Michael DeCarbo, 908-740-1807     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Late-Breaker Presentation of Overall Survival and Progression-Free Survival Results from Pivotal Phase 3 KEYNOTE-189 Trial with KEYTRUDA \u00ae (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy in First-Line Treatment of Advanced Nonsquamous Non-Small Cell Lung Cancer First-Time KEYTRUDA Data Including Recurrence-Free Survival from Phase 3 KEYNOTE-054 Study, in Collaboration with EORTC, in Patients with Stage III Surgically Resected High-Risk Melanoma Additional Research with KEYTRUDA, Investigational STING Agonist (MK-1454) and Merck\u2019s Collaboration with AstraZeneca for LYNPARZA \u00ae (olaparib) to be Presented Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new research from Merck\u2019s broad oncology clinical program \u2013 across several major tumor types, as monotherapy and in combination \u2013 will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2018 in Chicago from April 14-18. For the first time, data from the<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,138,289],"class_list":["post-745750","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology-newsroom","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>First-Line Lung Cancer Data and Other New Research from Merck\u2019s Broad Oncology Program to be Presented at AACR Annual Meeting - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/first-line-lung-cancer-data-and-other-new-research-from-mercks-broad-oncology-program-to-be-presented-at-aacr-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"First-Line Lung Cancer Data and Other New Research from Merck\u2019s Broad Oncology Program to be Presented at AACR Annual Meeting - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Late-Breaker Presentation of Overall Survival and Progression-Free Survival Results from Pivotal Phase 3 KEYNOTE-189 Trial with KEYTRUDA \u00ae (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy in First-Line Treatment of Advanced Nonsquamous Non-Small Cell Lung Cancer First-Time KEYTRUDA Data Including Recurrence-Free Survival from Phase 3 KEYNOTE-054 Study, in Collaboration with EORTC, in Patients with Stage III Surgically Resected High-Risk Melanoma Additional Research with KEYTRUDA, Investigational STING Agonist (MK-1454) and Merck\u2019s Collaboration with AstraZeneca for LYNPARZA \u00ae (olaparib) to be Presented Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new research from Merck\u2019s broad oncology clinical program \u2013 across several major tumor types, as monotherapy and in combination \u2013 will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2018 in Chicago from April 14-18. For the first time, data from the\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/first-line-lung-cancer-data-and-other-new-research-from-mercks-broad-oncology-program-to-be-presented-at-aacr-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:27:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"31 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/first-line-lung-cancer-data-and-other-new-research-from-mercks-broad-oncology-program-to-be-presented-at-aacr-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/first-line-lung-cancer-data-and-other-new-research-from-mercks-broad-oncology-program-to-be-presented-at-aacr-annual-meeting\\\/\",\"name\":\"First-Line Lung Cancer Data and Other New Research from Merck\u2019s Broad Oncology Program to be Presented at AACR Annual Meeting - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2018-03-14T18:30:00+00:00\",\"dateModified\":\"2025-11-07T06:27:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/first-line-lung-cancer-data-and-other-new-research-from-mercks-broad-oncology-program-to-be-presented-at-aacr-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/first-line-lung-cancer-data-and-other-new-research-from-mercks-broad-oncology-program-to-be-presented-at-aacr-annual-meeting\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/first-line-lung-cancer-data-and-other-new-research-from-mercks-broad-oncology-program-to-be-presented-at-aacr-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"First-Line Lung Cancer Data and Other New Research from Merck\u2019s Broad Oncology Program to be Presented at AACR Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"First-Line Lung Cancer Data and Other New Research from Merck\u2019s Broad Oncology Program to be Presented at AACR Annual Meeting - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/first-line-lung-cancer-data-and-other-new-research-from-mercks-broad-oncology-program-to-be-presented-at-aacr-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"First-Line Lung Cancer Data and Other New Research from Merck\u2019s Broad Oncology Program to be Presented at AACR Annual Meeting - Merck.com","og_description":"Late-Breaker Presentation of Overall Survival and Progression-Free Survival Results from Pivotal Phase 3 KEYNOTE-189 Trial with KEYTRUDA \u00ae (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy in First-Line Treatment of Advanced Nonsquamous Non-Small Cell Lung Cancer First-Time KEYTRUDA Data Including Recurrence-Free Survival from Phase 3 KEYNOTE-054 Study, in Collaboration with EORTC, in Patients with Stage III Surgically Resected High-Risk Melanoma Additional Research with KEYTRUDA, Investigational STING Agonist (MK-1454) and Merck\u2019s Collaboration with AstraZeneca for LYNPARZA \u00ae (olaparib) to be Presented Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new research from Merck\u2019s broad oncology clinical program \u2013 across several major tumor types, as monotherapy and in combination \u2013 will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2018 in Chicago from April 14-18. For the first time, data from the","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/first-line-lung-cancer-data-and-other-new-research-from-mercks-broad-oncology-program-to-be-presented-at-aacr-annual-meeting\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:27:26+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"31 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/first-line-lung-cancer-data-and-other-new-research-from-mercks-broad-oncology-program-to-be-presented-at-aacr-annual-meeting\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/first-line-lung-cancer-data-and-other-new-research-from-mercks-broad-oncology-program-to-be-presented-at-aacr-annual-meeting\/","name":"First-Line Lung Cancer Data and Other New Research from Merck\u2019s Broad Oncology Program to be Presented at AACR Annual Meeting - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2018-03-14T18:30:00+00:00","dateModified":"2025-11-07T06:27:26+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/first-line-lung-cancer-data-and-other-new-research-from-mercks-broad-oncology-program-to-be-presented-at-aacr-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/first-line-lung-cancer-data-and-other-new-research-from-mercks-broad-oncology-program-to-be-presented-at-aacr-annual-meeting\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/first-line-lung-cancer-data-and-other-new-research-from-mercks-broad-oncology-program-to-be-presented-at-aacr-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"First-Line Lung Cancer Data and Other New Research from Merck\u2019s Broad Oncology Program to be Presented at AACR Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"5d2fa2c1-da3a-4cf1-b6b5-22cfece44988","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/First-Line-Lung-Cancer-Data-and-Other-New-Research-from-Mercks-Broad-Oncology-Program-to-be-Presented-at-AACR-Annual-Meeting-2018.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745750","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745750\/revisions"}],"predecessor-version":[{"id":3675110,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745750\/revisions\/3675110"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745750"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745750"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}